文献速递瓣膜外科

经颈动脉与经股动脉入路TAVR的结果比较

Results of transcarotid compared with transfemoral transcatheter aortic valve replacement.
PubMed 文献 · J Thorac Cardiovasc Surg · 2020-04-13

本研究为单中心研究,纳入2015至2019年526例TAVR患者,其中经颈动脉(TC)127例、经股动脉(TF)399例。TC组糖尿病、COPD、冠心病及外周血管病患病率更高,但院内死亡、30天卒中、操作成功率、30天累积死亡、主要血管并发症及大/危及生命出血均与TF组相似,1年生存及无神经事件也无差异。结论认为TC是TAVR安全替代入路,尽管TC患者疾病负担更高,结局与TF-TAVR相似。

要点

  • TC-TAVR患者合并糖尿病、COPD、冠心病及外周血管病比例高于TF组。
  • 院内死亡、30天卒中、操作成功率等主要结局在TC与TF组间无显著差异。
  • 1年生存率及无神经事件在两组间无差异,TC可作为TF不适合者的替代入路。

核心结论

  • TC入路是TAVR的安全替代入路,尽管TC患者疾病负担更高,其结局与TF-TAVR相似。

研究设计与样本

  • 单中心研究,纳入2015至2019年连续526例TAVR患者,TC-TAVR 127例,TF-TAVR 399例。
  • 采用多变量logistic回归模型按主要入路(TC vs TF)评估术后及30天临床事件,并评估1年生存及无神经事件。

主要发现

  • TC组糖尿病、COPD、冠心病及外周血管病患病率高于TF组。
  • 1年随访时两组生存及神经事件无差异。

临床怎么用

  • 对于不适合TF入路的TAVR患者,TC可作为安全替代入路,其结局与TF-TAVR相似。

局限性

  • 本研究为单中心研究,结果需多中心验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The femoral artery is the preferred vascular access to perform transcatheter aortic valve replacement (TAVR). However, the optimal alternative approach has not been elucidated in patients who are not candidates for a transfemoral (TF) access. The objective of this study was to compare the outcomes of TAVR performed by the transcarotid (TC) compared with the TF approach. METHODS: This was a single-center study that included 526 consecutive patients who underwent TAVR between 2015 and 2019. TC-TAVR was performed in 127 and TF-TAVR in 399 patients. Postprocedural and 30-day clinical events were evaluated according to main access (TC vs TF) using a multivariate logistic regression model. One-year survival and freedom from neurological events were also evaluated. RESULTS: The prevalence of diabetes, chronic obstructive pulmonary disease, coronary artery disease, and peripheral vascular disease was higher in the TC group. In-hospital mortality (3.2% vs 2.0%, adjusted odds ratio, 1.83; 95% confidence interval, 0.47-7.15; P = .39), and 30-day stroke (2.4% vs 3.3%; odds ratio, 0.84; 95% confidence interval, 0.21-3.41; P = .81), were similar between groups as were other outcomes: procedural success (98.4% vs 97.0%; P = .52), 30-day cumulative mortality (4.8% vs 2.8%; P = .26), major vascular complication (2.4% vs 4.5%; P = .25), and major/life-threatening bleeding (4.7% vs 6.0%; P = .41) (TC vs TF, respectively). No differences were found among groups regarding survival or neurological events at 1-year follow-up. CONCLUSIONS: The TC approach is a safe alternate-access strategy for TAVR, and is associated with similar outcomes compared with TF-TAVR, despite a higher disease burden in TC patients.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Junquera L, Kalavrouziotis D, Côté M, et al. Results of transcarotid compared with transfemoral transcatheter aortic valve replacement. J Thorac Cardiovasc Surg. 2020. PMID: 32387164. doi:10.1016/j.jtcvs.2020.03.091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。